MOUNTAIN VIEW, Calif., Nov. 6 /PRNewswire/ -- Frost & Sullivan today announced that the 2008 European Technology Innovation of the Year Award in molecular/cellular imaging has been bestowed upon Aposense Ltd., for its pioneering molecular platform for the targeting and imaging of apoptosis.
Israeli-based Aposense's technology platform, known as Aposense(R), is an innovative set of rationally designed molecules specifically targeting apoptosis (programmed cell death), both for medical imaging, personalised medicine, and for targeted drug design.
"The modular structure of Aposense(R) molecules allows a broad range of imaging moieties for clinical imaging to be attached and targeted to apoptotic cells," notes Frost & Sullivan Research Analyst Katherine Austin. "Drugs can also be targeted to apoptotic cells and tissues with Aposense(R). This important characteristic makes Aposense(R) technology applicable to various imaging modalities and targeted therapeutics."
The Aposense(R) lead-compound for molecular imaging, ML-10, enables real-time visualisation of biological activity in the clinic using a standard positron emission tomography (PET) scanner following radio-labeling of the ML-10 agent with the isotope 18-F, which is used for most other PET procedures. It can be used in the diagnosis of disease as well as disease staging, and also for monitoring response to therapy. It can also be integrated as a valuable tool in the drug development processes.
"In the field of oncology, Aposense(R) ML-10 allows clinicians to see
response of tumors to anti-cancer treatment within hours or days, compared
with the use of current technologies such as computerised tomography or
magnetic resonance imaging, which require weeks or months before the
therapeutic effects can be visualised," says Austin. "Standard imaging
technologies reveal treatment effects only at the anatomical level, while
with Aposense(R), the biological effect can be seen much earlier
|SOURCE Frost & Sullivan|
Copyright©2008 PR Newswire.
All rights reserved